Maritime Type 2 Diabetes Study

Type 2 diabetes happens when the body does not use insulin well or does not make enough of it. Insulin helps move sugar from the blood into the body’s cells for energy. Excess body weight and low physical activity are linked with a higher risk. Over time, high blood sugar can damage the eyes, kidneys and nerves, and increase the risk of heart and blood vessel problems. Managing blood sugar can become an ongoing part of daily life.

Current care includes healthy eating, physical activity and medicines to help manage blood sugar. These may include tablets such as metformin and SGLT-2 medicines, and injectable treatments. Some people’s blood sugar remains above target despite treatment.

This study will compare an investigational medicine with semaglutide to see how they affect blood sugar and weight. Researchers will also check its safety and side effects. 

If you are eligible and choose to take part, you will be assigned by chance to either the investigational medicine or semaglutide, with an equal chance of receiving either. 

Both treatments are given as injections under the skin. The investigational medicine is given by clinic staff, while the semaglutide will typically be injected at home - the study team will instruct you on how to administer the injection yourself. 

You will attend approximately 21 planned clinic visits over up to 84 weeks. Eye checks may need separate appointments, and extra visits may be needed. 

Checks include a review of your health and medicines, blood and urine samples, weight and waist measurements, blood pressure and pulse checks, heart recordings, and eye checks with photographs. You will complete questionnaires about diabetes and your wellbeing. 

You will be given a blood sugar meter and training to check your blood sugar at home. You will record low blood sugar episodes and other readings as directed. Diabetes education, including diet and activity advice, is provided as needed.